Trefoil Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to restore vision for people with corneal diseases. The company’s lead engineered fibroblast growth factor, TTHX1114, is being advanced in multiple formulations to treat both endothelial and epithelial corneal conditions—potentially offering pharmaceutical options where none currently exist.